ScholarIQanswers from OpenAlex
Clinical Lung Cancer
JournalCitation impact & published research
Clinical Lung Cancer is a journal indexed in ScholarIQ from OpenAlex.
How many works does Clinical Lung Cancer have?
ScholarIQindexed works
Clinical Lung Cancer has 3,217 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Clinical Lung Cancer have?
ScholarIQcitation count
Clinical Lung Cancer has 61,786 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Clinical Lung Cancer?
ScholarIQh-index
Clinical Lung Cancer has an h-index of 92 in OpenAlex.
What is the article processing charge of Clinical Lung Cancer?
ScholarIQarticle processing charge
Clinical Lung Cancer lists an article processing charge of 3,110 USD in OpenAlex.
What is the OpenAlex record for Clinical Lung Cancer?
ScholarIQopenalex
The OpenAlex for Clinical Lung Cancer is on the source record.
What are the most-cited papers on Clinical Lung Cancer?
ScholarIQmost cited works
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Giulio Metro, Fabiana Perrone, Marcello Tiseo, Melissa Bersanelli, Paola Bordi, Daniele Santini, Raffaele Giusti, Antonino Grassadonia, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Federica Zoratto, Enzo Veltri, Francesco Malorgio, Carlo Garufi, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Daniela Iacono, Maria Rita Migliorino, Giampiero Porzio, Katia Cannita, Corrado Ficorella, Sebastiano Buti
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
Yusuke Okuma, Hiroshi Wakui, Hirofumi Utsumi, Yukiko Sagawa, Yukio Hosomi, Kazuyoshi Kuwano, Sadamu Homma
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer
Satoru Kitazono, Yutaka Fujiwara, Koji Tsuta, Hirofumi Utsumi, Shintaro Kanda, Hidehito Horinouchi, Hiroshi Nokihara, Noboru Yamamoto, Shinji Sasada, Shun-ichi Watanabe, Hisao Asamura, Tomohide Tamura, Yuichiro Ohe
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer
Hui Xia, Xingyang Xue, Huaxin Ding, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Xingsheng Hu, Sai‐Hong Ignatius Ou
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna, Giampiero Porzio, Melissa Bersanelli, Federico Cappuzzo, Joachim G.J.V. Aerts, Raffaele Giusti, Emilio Bria, Diego Cortinovis, Francesco Grossi, Maria Rita Migliorino, Domenico Galetta, Francesco Passiglia, Rossana Berardi, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alessandro Tuzi, Alain Gelibter, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Alessandro Inno, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Matteo Santoni, Marianna Tudini, Michele Ghidini, Marco Filetti, Annamaria Catino, Pamela Pizzutilo, Luca Sala, Mario Occhipinti, Fabrizio Citarella, Marco Russano, Mariangela Torniai, Luca Cantini, Alessandro Follador, Vincenzo Sforza, Olga Nigro, Miriam Grazia Ferrara, Ettore D’Argento, Alessandro Leonetti, Linda Pettoruti, Lorenzo Antonuzzo, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Cinzia Baldessari, Federica Bertolini, Luigi Della Gravara, Maria Giovanna Dal Bello, Robert A. Belderbos, Marco De Filippis, Cristina Cecchi, Serena Ricciardi, Clelia Donisi, Alessandro De Toma, Claudia Proto, Alfredo Addeo, Ornella Cantale, Biagio Ricciuti, Carlo Genova, Alessandro Morabito, Daniele Santini, Corrado Ficorella, Katia Cannita